Skip Navigation Links

Bookmark and Share
Henlius’ 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration

on 12/3/2021
SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Me...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.